StreetInsider.com News Articles

Form 4 VOLITIONRX LTD For: Sep 28 Filed by: Forterre Gael

Wed, 30 Sep 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260930/27129337.html

Form 4 VOLITIONRX LTD For: Sep 28 Filed by: Michel Gaetan

Wed, 30 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260930/27129328.html

Form 8-K VOLITIONRX LTD For: Sep 22

Fri, 25 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260925/27108097.html

VolitionRx joins €6.3M French sepsis detection program

Thu, 17 Sep 2026 09:17:38 -0400

VolitionRx Limited (NYSE American: VNRX) has shared details about its participation in the DETECSEPS program, a government-funded initiative in France focused on the early detection of sepsis in emergency department patients.

The program, which received €6.3 million (~$7.3 million) in funding, is part of France's 2030 plan and was selected through a "Challenge Prevention" call for proposals by the French Health Innovation Agency. The DETECSEPS Consortium includes AP-HP, Hospices Civils de Lyon, IDS France, and Volition.

The program aims to identify, upon arrival at the emergency department, which patients with suspected infection are at risk of developing sepsis and which can be

VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France

Thu, 17 Sep 2026 09:17:00 -0400

HENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (XASE: VNRX) (together with affiliates "Volition"), a multi-national epigenetics company, as part of the Government-funded DETECSEPS Consortium in France, today shares further details about the official launch of the project on the early detection of sepsis.

VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France

Thu, 17 Sep 2026 09:17:00 -0400

VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France

Thu, 17 Sep 2026 09:17:00 -0400

VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France

Thu, 17 Sep 2026 09:17:00 -0400

VolitionRx Participates in Launch of DETECSEPS Program in France

Thu, 17 Sep 2026 08:17:00 -0400

French Government-Funded €6.3 million (~$7.3 million) Consortium Selects Volition's Nu.Q® NETs Assay as Sole Biomarker for France's Real World Evaluation of Early Detection of Sepsis

HENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (XASE: VNRX) (together with affiliates, "Volition"), a multi-national epigenetics company, today announces, as part of the

VolitionRx Participates in Launch of DETECSEPS Program in France

Thu, 17 Sep 2026 08:17:00 -0400

VolitionRx Participates in Launch of DETECSEPS Program in France

Thu, 17 Sep 2026 08:17:00 -0400

VolitionRx Participates in Launch of DETECSEPS Program in France

Thu, 17 Sep 2026 08:17:00 -0400

Form SCHEDULE 13D/A VOLITIONRX LTD Filed by: Lagoda Investment Management, L.P.

Wed, 16 Sep 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260916/27071254.html

Form 8-K VOLITIONRX LTD For: Sep 09

Tue, 15 Sep 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260915/27065671.html

Form 8-K VOLITIONRX LTD For: Sep 11

Mon, 14 Sep 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260914/27059019.html

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

Mon, 14 Sep 2026 08:17:00 -0400

Reduces Equity Overhang

HENDERSON, Nev., Sept. 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the outstanding balance on its senior secured convertible promissory note, dated May 20, 2025, in the original principal amount of $7,500,000 (the "Note"), issued to Lind Global Asset Management XII LLC ("Lind"). Following the pre-payment,

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

Mon, 14 Sep 2026 08:17:00 -0400

Reduces Equity Overhang

Form EFFECT VOLITIONRX LTD

Fri, 11 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260911/27050449.html

Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference

Thu, 10 Sep 2026 08:17:00 -0400

Targets $36 Billion TAM in Early Cancer Detection and MRD.

HENDERSON, Nev., Sept. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract¹ at the European Society of Medical Oncology Molecular Analysis for Precision Oncology Conference (ESMO MAP) in London this week. The presentation entitled "Early stage I solid cancer detection by direct ChIP-seq of short CTCF-protected plasma ctDNA" and given by Dr. Andrew Retter, highlights the use of its Capture-Seq™ technology in the detection of early-stage I solid cancer.

Dr Andrew

Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference

Thu, 10 Sep 2026 08:17:00 -0400

Targets $36 Billion TAM in Early Cancer Detection and MRD.
HENDERSON, Nev., Sept. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract¹ at the European Society of Medical Oncology Molecular Analysis for Precision Oncology Conference (ESMO MAP) in London this week. The presentation entitled "Early stage I solid cancer detection by direct ChIP-seq of short CTCF-protected plasma ctDNA" and given by Dr. Andrew Retter, highlights the use of its Capture-Seq™ technology in the detection of early-stage I solid cancer.

Dr Andrew

Form S-3/A VOLITIONRX LTD

Wed, 09 Sep 2026 06:04:00 -0400
si-local-file:///var/storage/secattach/20260909/27038705.html

Form S-3/A VOLITIONRX LTD

Tue, 08 Sep 2026 17:09:00 -0400
si-local-file:///var/storage/secattach/20260908/27037501.html

Form SCHEDULE 13D VOLITIONRX LTD Filed by: Lagoda Investment Management, L.P.

Fri, 04 Sep 2026 17:30:00 -0400
si-local-file:///var/storage/secattach/20260904/27030747.html

Form 8-K VOLITIONRX LTD For: Sep 02

Wed, 02 Sep 2026 16:46:00 -0400
si-local-file:///var/storage/secattach/20260902/27019820.html

Form 8-K VOLITIONRX LTD For: Aug 27

Wed, 02 Sep 2026 06:05:00 -0400
si-local-file:///var/storage/secattach/20260902/27015143.html